Trial Profile
Bevacizumab + Folfox4 or Xelox2 as first- line treatment in colorectal cancer. Randomized phase II study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Status changed from recruiting to completed according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 22 Mar 2012 New trial record